Skip to main content
Clinical Trials/ACTRN12605000211662
ACTRN12605000211662
Completed
Phase 2

Intravitreal triamcinolone injection for treatment of clinically significant diabetic macular oedema that persists after laser treatment

Professor Mark Gillies0 sites70 target enrollmentAugust 25, 2005

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Diabetic Macular Oedema
Sponsor
Professor Mark Gillies
Enrollment
70
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 25, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Professor Mark Gillies

Eligibility Criteria

Inclusion Criteria

  • Clinically significant diabetic macular oedema involving the fovea in one or both eyes (phakic and/or pseudophakic) which persists at least 3 months after adequate macular photocoagulation. Best corrected visual acuity in the affected eye(s) 6/9 or worse.

Exclusion Criteria

  • Glaucoma which is uncontrolled or is controlled but with glaucomatous visual field defects. Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration). Significant macular ischemia (FFA). No useful vision in fellow eye. Known allergies to triamcinolone acetate or steroids. Patient is already under systemic treatment with \> 5mg prednisolone (or equivalent) daily. Intercurrent severe disease such as septicaemia. Any condition which would affect follow\-up or photographic documentation (e.g. geographical, psycho\-social, media opacities).

Outcomes

Primary Outcomes

Not specified

Similar Trials